Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Nov 1;43(41):4378-4388.
doi: 10.1093/eurheartj/ehac472.

Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial

Henrique Andrade R Fonseca  1 , Remo Holanda M Furtado  1   2   3 , André Zimerman  4 , Pedro A Lemos  2 , Marcelo Franken  2 , Frederico Monfardini  1 , Rodrigo P Pedrosa  5 , Rodrigo de Lemos S Patriota  5 , Luiz Carlos S Passos  6 , Frederico Toledo C Dall'Orto  7 , Conrado R Hoffmann Filho  8 , Bruno Ramos Nascimento  9 , Felipe A Baldissera  10 , Cesar Augusto C Pereira  3 , Paulo Ricardo A Caramori  11 , Pedro Beraldo de Andrade  12 , Carlos Esteves  1 , Elke Ferreira Salim  1 , Jefferson Henrique da Silva  1 , Izabela Chave Pedro  1 , Mariana Castaldi R Silva  1 , Ewerton Hernandes de Pedri  1 , Ana Carla R D Carioca  1 , Luciana Pereira A de Piano  1 , Camila Santos N Albuquerque  1 , Diogo D F Moia  1 , Roberta Grazzielli R A P Momesso  1 , Felipe P Machado  1 , Lucas P Damiani  1 , Ronaldo Vicente P Soares  1 , Guilherme P Schettino  13 , Luiz V Rizzo  13 , José Carlos Nicolau  3 , Otávio Berwanger  1
Affiliations
Randomized Controlled Trial

Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial

Henrique Andrade R Fonseca et al. Eur Heart J. .

Abstract

Aims: To evaluate whether a strategy of double-dose influenza vaccination during hospitalization for an acute coronary syndrome (ACS) compared with standard-dose outpatient vaccination (as recommended by current guidelines) would further reduce the risk of major cardiopulmonary events.

Methods and results: Vaccination against Influenza to Prevent cardiovascular events after Acute Coronary Syndromes (VIP-ACS) was a pragmatic, randomized, multicentre, active-comparator, open-label trial with blinded outcome adjudication comparing two strategies of influenza vaccination following an ACS: double-dose quadrivalent inactivated vaccine before hospital discharge vs. standard-dose quadrivalent inactivated vaccine administered in the outpatient setting 30 days after randomization. The primary outcome was a hierarchical composite of all-cause death, myocardial infarction, stroke, unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory causes, analysed by the win ratio method. Patients were followed for 12 months. During two influenza seasons, 1801 participants were included at 25 centres in Brazil. The primary outcome was not different between groups, with 12.7% wins in-hospital double-dose vaccine group and 12.3% wins in the standard-dose vaccine group {win ratio: 1.02 [95% confidence interval (CI): 0.79-1.32], P = 0.84}. Results were consistent for the key secondary outcome, a hierarchical composite of cardiovascular death, myocardial infarction and stroke [win ratio: 0.94 (95% CI: 0.66-1.33), P = 0.72]. Time-to-first event analysis for the primary outcome showed results similar to those of the main analysis [hazard ratio 0.97 (95% CI: 0.75-1.24), P = 0.79]. Adverse events were infrequent and did not differ between groups.

Conclusion: Among patients hospitalized with an ACS, double-dose influenza vaccination before discharge did not reduce cardiopulmonary outcomes compared with standard-dose vaccination in the outpatient setting.

Clinical trial registration: ClinicalTrials.gov number: NCT04001504.

Keywords: Acute coronary syndrome; Hospitalization; Immunization; Influenza vaccine; Mortality; Myocardial infarction; Stroke.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: H.A.R.F. reports research grants from AstraZeneca and Brazilian Ministry of Health; R.H.M.F. reports research grants and personal fees from AstraZeneca, Bayer, Biomm and Servier; and research grants from Amgen, Pfizer, EMS, Aché, CytoDin, Brazilian Ministry of Health, University Health Network (received from his institution), and Lemann Foundation Research Fellowship. A.Z. reports research scholarships from the Brazilian National Council for Scientific and Technological Development (CNPq) and the Lemann Foundation Research Fellowship; M.F. reports research grants from Brazilian Ministry of Health; P.A.L., supported in part by a grant from The National Council for Scientific and Technological Development (CNPq)—Brazil (grant # 308733/2016-9); non-paid clinical advisor of Flouit, a scientific computing initiative; part of Argonauts, an innovation facilitator; B.R.N. is partially financed CNPq (Bolsa de produtividade em pesquisa, 312382/2019-7), by the Edwards Lifesciences Foundation (Improving the Prevention and Detection of Heart Valve Disease Across the Lifespan, 2021) and by FAPEMIG (grant APQ-000627-20); J.C.N. reports research grants from Amgen, Astrazeneca, Bayer, CSL Behring, Daiichi Sankyo, Dalcor, Esperion, Janssen, Novartis, NovoNordisk, Sanofi and Vifor, research support from the Brazilian Council for Scientific and Technological Development (CNPq); O.B. received research grants (paid to his institution) from AstraZeneca, Pfizer, Bayer, Amgen, Servier, BMS, and Novartis. The other authors declare no conflict of interest.

Comment in

Publication types

MeSH terms

Substances

Associated data